Teva Pharmaceutical Industries Ltd (TEVA): Shareholders' Equity
$7.91B
As of 2025-12-31
$7.76B
As of 2026-06-30
-2.7%
3-year compound annual growth
-6.5%
5-year compound annual growth
-12.5%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.91B | +47.1% | 2026-02-03, Balance as of period end |
| 2024-12-31 | $5.38B | -33.8% | 2026-02-03, Balance as of period end |
| 2023-12-31 | $8.13B | n/a | 2026-02-03, Balance as of period end |
| 2023-09-30 | $7.39B | n/a | 2024-02-12, Balance as of period end |
| 2023-06-30 | $7.59B | n/a | 2024-02-12, Balance as of period end |
| 2023-03-31 | $8.50B | n/a | 2024-02-12, Balance as of period end |
| 2022-12-31 | $8.60B | n/a | 2025-02-05, Balance as of period end |
| 2022-09-30 | $9.51B | n/a | 2024-02-12, Balance as of period end |
| 2022-06-30 | $9.81B | n/a | 2024-02-12, Balance as of period end |
| 2021-12-31 | $11.24B | +1.7% | 2024-02-12, Balance as of period end |
| 2020-12-31 | $11.06B | -26.6% | 2023-02-10, Balance as of period end |
| 2019-12-31 | $15.06B | -4.6% | 2022-02-09, Balance as of period end |
| 2018-12-31 | $15.79B | -15.7% | 2021-02-10, Balance as of period end |
| 2017-12-31 | $18.75B | -46.4% | 2020-02-21, Balance as of period end |
| 2016-12-31 | $34.99B | +16.9% | 2019-02-19, Balance as of period end |
| 2015-12-31 | $29.93B | +28.1% | 2018-02-12, Balance as of period end |
| 2014-12-31 | $23.36B | +3.2% | 2017-02-15, Balance as of period end |
| 2013-12-31 | $22.64B | -1.0% | 2016-02-11, Balance as of period end |
| 2012-12-31 | $22.87B | +2.3% | 2015-02-09, Balance as of period end |
| 2011-12-31 | $22.34B | +1.5% | 2014-02-10, Balance as of period end |
| 2010-12-31 | $22.00B | +14.2% | 2013-02-12, Balance as of period end |
| 2009-12-31 | $19.26B | +17.2% | 2013-02-12, Balance as of period end |
| 2008-12-31 | $16.44B | +18.6% | 2011-02-15, Balance as of period end |
| 2007-12-31 | $13.86B | n/a | 2010-02-22, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $7.91B | +47.1% |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $31.26B | +6.5% |
| Viatris Inc (VTRS) | 2025-12-31 | $14.71B | -21.1% |
| Vertex Pharmaceuticals Inc (VRTX) | 2025-12-31 | $18.67B | +13.7% |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $377.00M | n/m |
| Zoetis Inc. (ZTS) | 2025-12-31 | $3.33B | -30.2% |
| Abbott Laboratories (ABT) | 2025-12-31 | $52.13B | +9.4% |
| Organon & Co. (OGN) | 2025-12-31 | $752.00M | +59.3% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $18.47B | +13.1% |
Compare TEVA, REGN, VTRS, VRTX side by side · Screen every company in Pharmaceutical Preparations ↗